Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477196 | 0.80 | SOS1 (0.37) | TAAR1LMNACHRNB4CHRNA3HTR2C | |
| SCHEMBL1429748 | 0.80 | ALOX15 (0.46) | LMNACYP2D6TSHRCHRNB4CHRNA3 | |
| SCHEMBL6483247 | 0.76 | SLC6A4 (0.41) | CYP1A2ADRA2AADRA2BADRA2CMAPT | |
| SCHEMBL1429703 | 0.71 | TAAR1 (0.49) | TAAR1LMNAADRA2AADRA2BADRA2C | |
| SCHEMBL11161143 | 0.71 | ADRA2A (0.41) | TAAR1LMNACYP1A2CYP2D6TSHR | |
| Diphenylmethane SCHEMBL28085719 | 0.69 | CALM1 (0.80) | LMNACALM1 | |
| Diphenylmethane SCHEMBL28072604 | 0.69 | CALM1 (0.80) | LMNACALM1 | |
| SCHEMBL28487686 | 0.68 | TAAR1 (0.50) | TAAR1LMNACYP1A2CYP2D6TSHR | |
| SCHEMBL11816040 | 0.67 | TSHR (0.40) | LMNACYP1A2TSHRMAPTMAOA | |
| SCHEMBL11597510 | 0.67 | TAAR1 (0.79) | TAAR1LMNACYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118203623-A | Application of radix Angelicae sinensis and radix astragali blood circulation promoting preparation in preparation of medicine for treating arteriosclerosis | 鲁南厚普制药有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117616069-A | Crosslinked silicone resin, method for producing same, and cosmetic | 信越化学工业株式会社 | 2024-02-27 | — | — | CN | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2001863-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-6936632-B2 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| CN-1191254-C | Fused pyrrole compounds, pharmaceutical composition containing the same, and the use thereof | MARCKLE GMBH (DE) | 2005-03-02 | — | — | CN | disclosed |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1246825-B1 | FUSED PYRROLE COMPOUNDS, PHARMACEUTICAL AGENTS CONTAINING THE SAME, AND THE USE THEREOF | MERCKLE GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
| CN-1418217-A | Fused pyrrole compounds, pharmaceutical composition containing the same, and the use thereof | MARCKLE GMBH (DE) | 2003-05-14 | — | — | CN | disclosed |
| EP-1246825-A1 | FUSED PYRROLE COMPOUNDS, PHARMACEUTICAL AGENTS CONTAINING THE SAME, AND THE USE THEREOF | MERCKLE GMBH (DE) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051491-A1 | FUSED PYRROLE COMPOUNDS, PHARMACEUTICAL AGENTS CONTAINING THE SAME, AND THE USE THEREOF | MERCKLE GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | TAAR1 805/4885LMNA 3996/4885CYP1A2 2460/4885 |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | PTGS1, PTGS2, PTGER1 | TAAR1 2005/4885LMNA 4779/4885CYP1A2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.